亚洲 · 区域市场 · The Financial Express
Nearly a quarter of cancer drugs see no price cut in latest NPPA review, study finds
A study reveals 24.7% of anti-cancer drugs saw no price drop under NPPA's trade margin rationalisation, as expensive MNC brands retained earlier MRPs.
在 The Financial Express 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.financialexpress.com)
